Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generex Oral-lyn vs Injected Insulin in Type 1 Diabetes
NCT00668850Phase 3Unknown
- Sponsor
- Generex Biotechnology Corporation
- Start
- Apr 2008
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of Generex Oral-lyn in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Generex Biotechnology Corporation. Primary endpoint: Glycosylated Haemoglobin HbA1c at Day 180. Status: unknown.
02
Drugs
Generex Oral-lyn
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00668850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668850.